ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "spondyloarthritis"

  • Abstract Number: L02 • ACR Convergence 2022

    Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

    Christopher Ritchlin1, Laura Coates2, Iain McInnes3, Philip J. Mease4, Joseph Merola5, Yoshiya Tanaka6, Akihiko Asahina7, Laure Gossec8, Alice Gottlieb9, Diamant Thaci10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Vish Shende11, Jason Coarse12 and Robert Landewé13, 1University of Rochester Medical Center, Rochester, NY, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 3College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 8Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, 9Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, 13Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
  • Abstract Number: L14 • ACR Convergence 2022

    Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

    Xenofon Baraliakos1, Atul Deodhar2, Désirée van der Heijde3, Marina Magrey4, Walter Maksymowych5, Tetsuya Tomita6, Huji Xu7, Marga Oortgiesen8, Ute Massow9, Carmen Fleurinck10, Alicia M Ellis8, Tom Vaux11, Julie Shepherd-Smith11, Alexander Marten9 and Lianne S Gensler12, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, 7Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), 8UCB Pharma, Morrisvile, NC, 9UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, 10UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 11UCB Pharma, Slough, United Kingdom, 12Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
  • Abstract Number: L15 • ACR Convergence 2022

    Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

    Xenofon Baraliakos1, Mikkel Østergaard2, Denis Poddubnyy3, Désirée van der Heijde4, Atul Deodhar5, Pedro M. Machado6, Victoria Navarro-Compán7, Kay Geert Hermann8, Mitsumasa Kishimoto9, Eun Young Lee10, Lianne S Gensler11, Uta Kiltz1, Marco Eigenmann12, Patricia Pertel13, Aimee Readie14, Hanno B. Richards12, Brian Porter15 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 6Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 7Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 8Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany, 9Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 10Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 11Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 12Novartis Pharma AG, Basel, Switzerland, 13Novartis Pharma AG, Reinach, Switzerland, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ, 15Novartis Pharmaceuticals Corporation, Far Hills, NJ

    Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in…
  • Abstract Number: 0057 • ACR Convergence 2022

    Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment

    Hannah Labinsky1, Sophie von Rohr2, Maria Gabriella Raimondo3, Ekaterina Vogt4, Britta Horstmann2, Isabel Gehring5, Jessica Rojas-Restrepo5, Fabian Proft6, Felix Mühlensiepen7, Daniela Bohr2, Georg Schett8, Andreas Ramming3 and Johannes Knitza3, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 4Thermo Fisher Scientific, Freiburg, Germany, 5Thermo Fisher Scientific, Freiburg, 6Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 7Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, 8Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: The growing shortage of rheumatologists threatens adequate rheumatological care. The diagnostic delay for axial spondyloarthritis (axSpA) is particularly long, ranging between 3 to 11…
  • Abstract Number: 0408 • ACR Convergence 2022

    Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status

    Philip C. Robinson1, Walter P Maksymowych2, Lianne Gensler3, Martin Rudwaleit4, Bengt Hoepken5, Lars Bauer5, Thomas Kumke5, Mindy Kim6 and Atul Deodhar7, 1University of Queensland School of Clinical Medicine, Brisbane, Australia, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 4University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Smyrna, GA, 7Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the…
  • Abstract Number: 0545 • ACR Convergence 2022

    Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)

    Cindy Weinstein1, Paula Sliwinska-Stanczyk2, Tomas Hala3, Marina Stanislav4, Anjela Tzontcheva5, Ruji Yao1, Yuliya Berd1, Sean Curtis1 and George Philip1, 1Merck & Co., Inc., Rahway, NJ, 2Reumatika Centrum Reumatologii, Warsaw, Poland, 3Center for Clinical and Basic Research, Pardubice, Czech Republic, 4Vladimirsky Moscow Regional Scientific Institution, Moscow, Russia, 5MSD Switzerland, Zürich, Switzerland

    Background/Purpose: Non-radiographic axial spondyloarthrits (nr-axSpA) is a rheumatic disease that is predominantly associated with chronic back pain and stiffness.1 Results from the Phase III GO-AHEAD…
  • Abstract Number: 1020 • ACR Convergence 2022

    Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review

    Vartika Kesarwani1, Stephanie Sinnappan2, M. Elaine Husni3, Michael Weisman4 and Joerg Ermann5, 1University of Connecticut, Farmington, CT, 2Brigham and Women's Hospital, Boston, MA, 3Cleveland Clinic, Cleveland, OH, 4Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or…
  • Abstract Number: 1165 • ACR Convergence 2022

    Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis

    Marie Beaufrère1, Manon Jacoutot1, Amel Ait Ali Said1, Roula Said-Nahal2, Gina Cosentino3, Chiara Rizzo3, Maxime Breban4 and Simon Glatigny4, 1Paris Saclay University / INSERM 1173, Montigny-le-Bretonneux, France, 2Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, 3INSERM 1173, Montigny-le-Bretonneux, France, 41INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France

    Background/Purpose: Spondylarthritis (SpA) is a group of chronic inflammatory disorders with osteoarticular and extraarticular symptoms, including colitis, highly associated with the human leukocyte antigen (HLA)…
  • Abstract Number: 1511 • ACR Convergence 2022

    Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis

    Dafna Gladman1, Ghaydaa Aldabie2, Fangya Ma3, Mitchell Sutton4, Ker-Ai Lee3 and Richard Cook3, 1Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3University of Waterloo, Waterloo, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
  • Abstract Number: 2119 • ACR Convergence 2022

    Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    M. Elaine Husni1, Philip J Mease2, Joseph Merola3, Frank Behrens4, Ennio Giulio Favalli5, Dennis McGonagle6, William Tillett7, Shigeyoshi Tsuji8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jason Coarse10, Jérémy Lambert11 and Laure Gossec12, 1Cleveland Clinic, Cleveland, OH, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 4Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 5University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 11UCB Pharma, Colombes, France, Irigny, France, 12Sorbonne Université, Paris, France

    Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
  • Abstract Number: 0373 • ACR Convergence 2022

    Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U

    Cristiana Sieiro Santos1, Isabel Sendino Tenorio1, Carolina Álvarez Castro1, Clara Moriano Morales2, Miguel Cordero Coma1 and Elvira Díez Álvarez1, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital León, León, Spain

    Background/Purpose: Uveitis is the most frequent extra-articular manifestation of spondylarthritis (SpA), characterized by a sudden onset, often unilateral, anterior and recurrent and may be the…
  • Abstract Number: 0409 • ACR Convergence 2022

    Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

    Philip J Mease1, Atul Deodhar2, Maxime Dougados3, Maureen Dubreuil4, Marina Magrey5, Helena Marzo-Ortega6, Martin Rudwaleit7, Christine de la Loge8, Alicia Ellis9, Carmen Fleurinck10, Marga Oortgiesen11, Vanessa Taieb12 and Lianne Gensler13, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Oregon Health & Science University, Portland, OR, USA, Portland, OR, 3Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 4Department of Rheumatology, Boston University School of Medicine, Boston, MA, 5Case Western Reserve University, University Hospitals, Richfield, OH, 6Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 7University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 8UCB Pharma, Brussels, Belgium, 9UCB Pharma, Raleigh, 10UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 11UCB Pharma, Raleigh, NC, 12UCB Pharma, Colombes, France, 13Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…
  • Abstract Number: 0547 • ACR Convergence 2022

    Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers

    Nicolas Rosine1, Surya Koturan1, Vincent Guillemot2, Claire Leloup1, Fanni Veress1, Tharshana Stephen1, Hanan Yahia-Cherbal1, Jérémie SELLAM3, Francis Berenbaum4, Natalia Pietrosemoli1, Elisabetta Bianchi1, Corinne MIceli5 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, 4Sorbonne University - Saint-Antoine hospital, Paris, France, 5APHP, Paris, France

    Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
  • Abstract Number: 1022 • ACR Convergence 2022

    Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis

    Walter P Maksymowych1, Anna Hadsbjerg2, Mikkel Østergaard3, Raphael Micheroli4, Susanne J. Pedersen5, Adrian Ciurea6, Nora Vladimirova2, Michael Nissen7, Kristyna Bubova8, Stephanie Wichuk9, Manouk de Hooge10, Ashish J Mathew11, Karlo Pintaric12, Monika gregova13, Ziga Snoj12, Marie Wetterslev14, Karel Gorican15, Joel Paschke16, Iris Eshed17 and Robert G Lambert9, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 3Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 4University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, 5Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 6University Hospital Zurich, Zürich, Switzerland, 7Hopitaux Universitaires de Genève, Geneva, Switzerland, 8First Faculty of Medicine, Charles University,, Prague, Czech Republic, 9University of Alberta, Edmonton, AB, Canada, 10Ghent University Hospital, Luxembourg, Luxembourg, 11Rigshospitalet, Copenhagen, Denmark, 12Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 13Institue of Rheumatology, Prague, 14Rigshospitalet, Copenhagen, Glostrup, Denmark, 15MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, 16CARE Arthritis LTD, Edmonton, AB, Canada, 17Sheba Medical Center, Tel Aviv, Israel

    Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list…
  • Abstract Number: 1243 • ACR Convergence 2022

    The Impact of MRI Slice Thickness on the Detection of Spinal Syndesmophytes in Axial Spondyloarthritis

    Kalliopi Klavdianou1, Alexaner Dieter Mewes2, Styliani Tsiami3, Philipp Sewerin4 and Xenofon Baraliakos5, 1'Asklepieion' General Hospital, Department of Rheumatology, Voula, Athens, Greece, 2University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, Dusseldorf, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Conventional radiographs (CR) are the gold standard for detecting syndesmophytes in axial Spondyloarthritis (axSpA), mainly because magnetic resonance imaging (MRI) is not able to…
  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences